Gastroenterology Unit, Bobigny, France; Departmental Committee of Cancers (93), Bondy, France.
Departmental Committee of Cancers (93), Bondy, France.
Dig Liver Dis. 2018 Dec;50(12):1339-1342. doi: 10.1016/j.dld.2018.02.008. Epub 2018 Mar 6.
In Europe, screening guidelines for colorectal cancer (CRC) recommend colonoscopy for high-risk patients and fecal immunological testing (FIT) for the standard-risk group. Currently, there is not any validated screening tool to exclude high-risk patients. The aim of the study is to evaluate the validity of exclusion and evaluate the follow-up of patients identified as increased risk for CRC. In this retrospective study using a prospective database, patients at increased risk were identified using the standardized form and then excluded from the FIT screening invitation. A specific questionnaire was sent to all patients at increased risk in order to confirm the reason for the exclusion and evaluate their follow-up. Among 220 695 eligible individuals, 16 693 (7.5%) were excluded after being characterized at increased risk using the standardized form. The questionnaire was sent to these 16.693 excluded patients and completed by 5076 (30.7%) patients. Validity of exclusion was confirmed in 92% of cases. Endoscopic follow-up was in agreement with guideline in 89% of persons at increased risk (inflammatory bowel disease 93%, personal history of CCR 92%, of colonic polyps 82%, family history of CRC 77%). This study suggests that the standardized form is a reliable tool to correctly exclude from the screening program 92% of patients at increased risk for CRC.
在欧洲,结直肠癌(CRC)的筛查指南建议对高危患者进行结肠镜检查,对标准风险组进行粪便免疫化学检测(FIT)。目前,尚无任何经过验证的筛查工具可排除高危患者。本研究旨在评估排除的有效性,并评估被确定为 CRC 风险增加的患者的随访情况。在这项使用前瞻性数据库的回顾性研究中,使用标准化表格确定了高风险患者,然后将其从 FIT 筛查邀请中排除。向所有高风险患者发送了一份专门的问卷,以确认排除的原因并评估其随访情况。在 220695 名符合条件的个体中,有 16693 名(7.5%)在用标准化表格确定为高风险后被排除。向这 16693 名被排除的患者发送了问卷,其中 5076 名(30.7%)患者完成了问卷。排除的有效性在 92%的病例中得到了确认。内镜随访与指南一致,在风险增加的人群中,89%(炎症性肠病 93%、CRC 个人史 92%、结肠息肉史 82%、CRC 家族史 77%)。这项研究表明,标准化表格是一种可靠的工具,可以正确地将 92%的 CRC 高风险患者排除在筛查计划之外。